Rubicon Research IPO Opens Today for Subscription: The Mumbai-based pharmaceutical company, Rubicon Research Limited, is opening its initial public offering (IPO) on Thursday, October 9, for subscription.
The Mumbai-based pharmaceutical’s IPO has been subscribed to around 0.13 times so far.
The IPO is worth Rs 877.5 crore and primarily comprises fresh capital and an offer for sale. For the investors who are planning to invest in the Rubicon Research IPO to make gains, here are all the details about the Rubicon Research IPO.
Rubicon Research IPO Opens Today: Check Subscription Status
Rubicon Research IPO has been subscribed to around 0.14 times so far, which includes 0.54 times subscription in the retail investors category, 0.14 times in the NII category by 11:54 am, according to Chittorgarh.com.
Rubicon Research IPO GMP Today
The IPO’s grey market premium (GMP) today indicated an upward trend in the listing. Rubicon Research IPO GMP stood at Rs 98, which indicates the IPO’s demand in the grey market. Considering its latest IPO GMP today, the Rubicon Research IPO is expected to be listed for Rs 583 (which is the sum of the cap price and latest GMP), according to investorgain.com. The IPO is expected to be listed at a percentage gain or loss per share of 20.21%.
Rubicon Research IPO: Price Band, Issue Size, Other Details
The IPO is a book build issue of Rs 1.377.5 crore, which includes a combination of fresh issue of 1.03 crore shares equivalent to Rs 500 crores. The company IPO includes offer for sale (OFS) of 1.81 crore shares aggregating to Rs 877.5 crore.
The IPO will open for subscription on October 9 and will conclude on October 13. The IPO allotment is expected to be finalised on October 14. The IPO will be listed on BSE and NSE with a tentative listing date at October 16.
Price Band, Lot Size, Other Details
The company has fixed Rs 461-Rs 485 per share as the price band. The lot size for the application is 30. The minimum investment for retailers is Rs 14,550 for 30 shares. The lot size for sNII is 14 lots, equivalent to 420 shares, ie Rs 2,03,700 and for bNII, it is 69 lots amounting to Rs 10,03,950.
Rubicon Research IPO: Should You Subscribe?
The US-centric strategy of expansion has helped Rubicon Research demonstrate exceptional growth, recording a total revenue CAGR of 75.89% between FY23 and FY25.
The company recorded a total revenue CAGR of 75.89% between FY23 and FY25, establishing it as one of the fastest-growing Indian pharmaceutical companies in its segment, noted SBI Securities.
Rubicon Research Limited is an innovation-led pharmaceutical formulations company with a product portfolio of 72 active ANDAs, 9 active NDAs and 1 OTC monography.
“At upper price band of Rs 485, the issue is valued at FY25 P/E multiple of 59.5x based on post-issue capital. During 1QFY26, the company has already achieved 27.4%/29.4%/32.2% of its FY25 Revenue/EBITDA/PAT respectively,” read SBI Securities report.
“With a high commercialization rate and a strong focus on regulatory compliance, Rubicon Research is strategically positioned to capitalize on opportunities in the global specialty and generic pharmaceutical landscape,” stated Ventura in its report. The brokerage has recommended investors to ‘subscribe’ the issue for long-term.